Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

Background & Aims: In the SYNERGY-NASH trial for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis, tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, effectively resolved MASH without worsening...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark L. Hartman, Rohit Loomba, Eric J. Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Yuanyuan Tang, Bram Brouwers, Mathijs C. Bunck, Axel Haupt, Arun J. Sanyal
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JHEP Reports
Subjects:
Tirzepatide
Glucose-dependent insulinotropic polypeptide
Glucagon-like peptide-1
Metabolic dysfunction-associated steatohepatitis
Subgroup analyses
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555925001508
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589555925001508

Similar Items